BOTHELL, Wash., Feb. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that it will host a conference call with investors and security analysts on Monday, March 3, 2008, at 11:30 a.m. Eastern time (8:30 a.m. Pacific time) to discuss the Company's corporate restructuring initiatives and future strategy. To participate in the live conference call, U.S. residents should dial (800) 901-5259 and international callers should dial (617) 786-4514. The access code for the live conference call is 46949609. To access the 24-hour telephone replay, U.S. residents should dial (888) 286-8010 and international callers should dial (617) 801-6888. The access code for the replay is 16918791.
Alternatively, to access the live audio webcast for this conference call or the subsequent archive, please go to Nastech's website at http://www.nastech.com approximately 15 minutes prior to the conference call in order to register and download any necessary software.
Nastech is a clinical stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on its proprietary molecular biology-based drug delivery technologies and, through its wholly-owned subsidiary, MDRNA, Inc., based on its proprietary ribonucleic acid interference (RNAi) technology. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
Nastech Forward-Looking Statements
Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech or a subsidiary to obtain additional funding; (ii) the ability of Nastech or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Nastech, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Nastech, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of Nastech, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contacts: Nastech Pharmaceutical Company Inc. Matthew Haines Senior Director, Investor Relations and Corporate Communications (212) 209-3874 firstname.lastname@example.org
Source: Nastech Pharmaceutical Company Inc.